Current status of pyrazoloacridine as an anticancer agent

Investigational New Drugs

Volumn 17, Issue 1, 1999, Pages 43-48

  Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acridine derivative; DNA intercalation; Pyrazoloacridine; Topoisomerases

Indexed keywords

ACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING);

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TUMOR MODEL;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INTERCALATING AGENTS; PYRAZOLES; TUMOR CELLS, CULTURED;

EID: 0032826587     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006242321596     Document Type: Review

References (22)

1. Jackson R, Sebolt J, Shillis J: The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Inv 8: 39-47, 1990
2. Capps D, Ross-Kesten S, Shillis J, Plowman J: 2-aminoalkyl-5-nitropyrazolo[3,4,5-k] acridines, a new class of anticancer agents (abstract). Proc Am Assoc Cancer Res 27: 277, 1986
3. Sebolt J, Scavone S, Pinter C: Pyrazoloacridines, a new class of antitumor agents with selectivity against solid tumors in vitro. Cancer Res 47: 4299-4304, 1987
4. LoRusso P, Wozniak AJ, Polin L: Antitumor efficacy of PD 115932 (NSC 366140) against solid tumors of mice. Cancer Res 50: 4900-4905, 1990
5. Sebolt J, Havlick M, Hamelehle K: Activity of the pyrazoloacridines against multidrug-resistant tumor cells. Cancer Chemother Pharmacol 24: 219-224, 1989
6. Cole SPC: Patterns of cross-resistance in a multidrug-resistance small cell lung carcinoma line. Cancer Chemother Pharmacol 26: 250-256, 1990
7. Sebolt-Leopold JS, Scavone SV: Biochemistry of the interactions between DNA and the pyrazoloacridines, a series of biologically novel anticancer agents. Proc Am Assoc Cancer Res 32: 334, 1991
8. Grem JL, Politi PM, Berg SL, Benchekroun NM, Patel M, Balis FM, Sinha BK, Dahut W, Allegra CJ: Cytotoxicity and DNA damage associated with pyrazolaacridine in MCF-7 breast cancer cells. Biochem Pharmacol 51(12): 1648-1659, 1996
9. Adjei AA, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J, Ames MM, Kaufmann SH: Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res 4(3): 683-691, 1998
10. Berg SL, Balis FM, McCully CL, Godwin KS, Poplack DG: Pharmacokinetics of pyrazoloacridine in the rhesus monkey. Cancer Res 51(20): 5467-5470, 1991
11. Rowinsky EK, Noe DA, Grochow LB, Sartorious SE, Bowling MK, Chen T-L, Lubejko BG, Kaufmann SH, Donehower RC: Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single and multiple dosing schedules. J Clin Oncol 13: 1975-1984, 1995
12. LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L: Phase I clinical trial of pyrazoloacridine NSC 366140 (PD 115934). Clin Cancer Res 1: 1487-1493, 1995
13. Monahan B, Quinn M, Takimoto C et al.: Phase I trial of pyrazoloacridine (PZA), a potent DNA binding agent, given as a weekly 24 hour continuous intravenous infusion in adult patients with refractory solid tumors. Proc Amer Soc Clin Oncol 17: 736, 1998
14. Berg SL, Blaney SM, Adamson PC, O'Brien M, Poplack DG, Arndt C, Blatt J, Balis FM: Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol 16(1): 181-186, 1998
15. Murgo AJ, Cannon D, Christian MC, Cheson B, Nelson AP: Clinical trials referral resource. Clinical trials with pyrazoloacridine. Oncology 11(7): 991-994, 1997
16. Zalupski MM, Shields AF, Philip PA, Kraut M, LoRusso P, Heilbrun LK, Vaitkevicius V: Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Invest New Drugs (16(1): 93-96, 1998
17. Small EJ, Fippin LJ, Whisenant SP: Pyrazoloacridine for the treatment of hormone-refractory prostate cancer. Cancer Invest 16(7): 456-461, 1998
18. Zalupski MM, Philip PA, LoRusso P, Shields AF: Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chemother & Pharmacol 40(3): 225-227, 1997
19. Mani S, Gerstner JB, Wade JL, Kugler JW et al.: Phase II trials of pyrazoloacridine (NSC 366140) in patients with advanced hepatobiliary and pancreatic cancer. Cancer Therapeutics 1: 313-317, 1998
20. Adjei AA, Budihardjo I, Rowinsky EK et al.: Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: Inhibition of platinum-DNA adduct removal. Clin Cancer Res 4: 683-691, 1998
21. Adjei AA, Kaufman SH, Reid J, Sloan JA, Alberts SR, Goldberg RM, Erlichman C: A phase I study of pyrazoloacridine (PZA) and carboplatin (CBDCA) in patients with advanced solid tumors. Proc Amer Assoc Cancer Res 39: 2206, 1998
22. Jackson RC: The problem of the quiescent cancer cell. Adv Enzyme Reg 29: 27-46, 1989